ArticleMedicine2026
Insights into the potential mechanism of Beiqishen Jiangtang Granule in the treatment of type 2 diabetes nephropathy: A study based on network pharmacology, molecular docking, and biological validation.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Beiqishen Jiangtang Granule, derived from Huangqi Liu Yi Tang and Shengmai Yin, plays a significant role for the therapy of type 2 diabetes mellitus (T2DM). However, the underlying molecular therapeutic mechanisms remain unclear. This study uses an integrated approach combining network pharmacology, molecular docking, and in vitro validation experiments to explore potential bioactive compounds, key targets, major signaling pathways, and underlying molecular mechanisms of Beiqishen Jiangtang Granule in the treatment of T2DM. In this study, network analysis was employed to screen metabolites and potential targets using the TCMSP database, followed by Gene Ontology, kyoto encyclopedia of genes and genomes enrichment analyses to predict the underlying mechanisms, and the protein encoded by the core target was docked with the active ingredient. Using a streptozotocin-induced approach, a T2DM rat model was established to evaluate the bioactivity of Beiqishen Jiangtang Granule on blood glucose levels, lipid profiles, inflammatory cytokines, gene expression, and gut microbiota composition. Network analysis identified 121 primary metabolites and 30 key targets in Beiqishen Jiangtang Granule. Integrated Gene Ontology and kyoto encyclopedia of genes and genomes analyses (27 items) predicted that Beiqishen Jiangtang Granule regulates serum contents of insulin, tumor necrosis factor-alpha, and interleukin-6, and modulates TP53, Akt, and PI3K protein expression to exert hypoglycemic effects. Animal studies confirmed Beiqishen Jiangtang Granule significant glucose-lowering action via these pathways and mRNA regulation. Additionally, Beiqishen Jiangtang Granule was shown to rebalance gut microbiota by enriching beneficial bacterial communities and suppressing the growth of harmful bacteria, aiding T2DM treatment. These findings demonstrate Beiqishen Jiangtang Granule's characterized by multiple components, targets, and pathways mechanisms in treating T2DM. Beiqishen Jiangtang Granule have a very significant therapeutic effect on T2DM by regulating the concentrations of insulin, tumor necrosis factor-alpha and interleukin-6 in serum and influencing the expressions of TP53, Akt and PI3K proteins and mRNA. In addition, Beiqishen Jiangtang Granule can also regulate the imbalance of intestinal flora related to T2DM in patients by promoting the proliferation of beneficial bacteria and inhibiting harmful bacteria, thereby assisting T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.